Sirnaomics Completes STP707 Phase I Clinical Study with Strong Safety Results

Sirnaomics Completes STP707 Phase I Clinical Study with Strong Safety Results

Sirnaomics Completes Successful Phase I Clinical Trial for STP707

Sirnaomics and STP707

Sirnaomics Ltd. is a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics. The company recently completed its STP707 Phase I study, which targeted patients with pancreatic cancer. STP707 is a small interfering RNA (siRNA) drug candidate that is administered through intravenous infusion.

STP707 Phase I Clinical Study

The STP707 clinical study involved six cohorts with 50 patients with various cancers, including 11 with pancreatic cancer. The study aimed to evaluate the safety, tolerability, and anti-tumor activity of the drug candidate. Patients with advanced/metastatic or surgically unresectable solid tumors, refractory to standard therapy, were recruited and received IV infusion over a 28-day cycle.

STP707 and Pancreatic Cancer

Pancreatic cancer is one of the deadliest tumor types, making Sirnaomics’ early safety and efficacy results for STP707 especially promising. For the 11 patients with pancreatic cancer in the study, the mean treatment cycles completed was three, with an average days for stable disease of 92 days. The longest stable disease for any of the pancreatic cancer patients was 302 days, demonstrating the potential efficacy of STP707 in treating this type of cancer.

The Future of STP707

The strong safety profile, long-lasting stable disease efficacy, and dose-dependent antitumor activity of STP707 make it a potential novel cancer therapeutic either as a single drug or in combination with immune checkpoint inhibitor drugs. Sirnaomics is currently undergoing a transition from a biotech company to a biopharma corporation, and STP707 represents a promising step forward in their RNA therapeutics pipeline.

About Sirnaomics

Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. The company focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. With its proprietary delivery technologies, Polypeptide Nanoparticle Formulation and the 2nd Generation of GalNAc Conjugates, the company has established an enriched drug candidate pipeline. Sirnaomics is actively advancing RNAi therapeutics for oncology, with multiple successes in their clinical programs for STP705 and STP707.

Conclusion

Sirnaomics’ completion of the STP707 Phase I clinical study represents a significant step forward in the development of RNA therapeutics for oncology. With a strong safety profile and promising efficacy results, STP707 could represent a novel cancer therapeutic and potentially be used in combination with other immune checkpoint inhibitor drugs. Sirnaomics’ commitment to discovering and developing innovative drugs for indications with medical needs and large market opportunities has positioned them as a leading biopharmaceutical company in the RNA therapeutics field.

Originally Post From https://www.prnewswire.com/news-releases/sirnaomics-announces-completion-of-stp707-phase-i-clinical-study-with-strong-safety-profile-and-disease-activity-for-the-treatment-of-pancreatic-cancer-patients-302185472.html

Read more about this topic at
mRNA-based cancer therapeutics
Recent Advances in RNA‐Targeted Cancer Therapy – Li

Regeneron Pharmaceuticals Stock Sparks Trading Frenzy on Friday

Roche’s Vabysmo gets CHMP nod for treating retinal vein occlusion in third indication RVO